Literature DB >> 9326332

Screening and diagnosis for the fragile X syndrome among the mentally retarded: an epidemiological and psychological survey. Collaborative Fragile X Study Group.

B B de Vries1, A M van den Ouweland, S Mohkamsing, H J Duivenvoorden, E Mol, K Gelsema, M van Rijn, D J Halley, L A Sandkuijl, B A Oostra, A Tibben, M F Niermeijer.   

Abstract

The fragile X syndrome is an X-linked mental retardation disorder caused by an expanded CGG repeat in the first exon of the fragile X mental retardation (FMR1) gene. Its frequency, X-linked inheritance, and consequences for relatives all prompt for diagnosis of this disorder on a large scale in all affected individuals. A screening for the fragile X syndrome has been conducted in a representative sample of 3,352 individuals in schools and institutes for the mentally retarded in the southwestern Netherlands, by use of a brief physical examination and the DNA test. The attitudes and reactions of (non)consenting parents/guardians were studied by (pre- and posttest) questionnaires. A total of 2,189 individuals (65%) were eligible for testing, since they had no valid diagnosis, cerebral palsy, or a previous test for the FMR1 gene mutation. Seventy percent (1,531/2,189) of the parents/guardians consented to testing. Besides 32 previously diagnosed fragile X patients, 11 new patients (9 males and 2 females) were diagnosed. Scoring of physical features was effective in preselection, especially for males (sensitivity .91 and specificity .92). Major motives to participate in the screening were the wish to obtain a diagnosis (82%), the hereditary implications (80%), and the support of research into mental retardation (81%). Thirty-four percent of the parents/guardians will seek additional diagnostic workup after exclusion of the fragile X syndrome. The prevalence of the fragile X syndrome was estimated at 1/ 6,045 for males (95% confidence interval 1/9,981-1/ 3,851). On the basis of the actual number of diagnosed cases in the Netherlands, it is estimated that >50% of the fragile X cases are undiagnosed at present.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9326332      PMCID: PMC1715962          DOI: 10.1086/515496

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  27 in total

1.  Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome.

Authors:  I Oberlé; F Rousseau; D Heitz; C Kretz; D Devys; A Hanauer; J Boué; M F Bertheas; J L Mandel
Journal:  Science       Date:  1991-05-24       Impact factor: 47.728

2.  Fragile X genotype characterized by an unstable region of DNA.

Authors:  S Yu; M Pritchard; E Kremer; M Lynch; J Nancarrow; E Baker; K Holman; J C Mulley; S T Warren; D Schlessinger
Journal:  Science       Date:  1991-05-24       Impact factor: 47.728

3.  Prevalence of fragile X syndrome.

Authors:  G Turner; T Webb; S Wake; H Robinson
Journal:  Am J Med Genet       Date:  1996-07-12

4.  A simple salting out procedure for extracting DNA from human nucleated cells.

Authors:  S A Miller; D D Dykes; H F Polesky
Journal:  Nucleic Acids Res       Date:  1988-02-11       Impact factor: 16.971

5.  Is it time for population-based prenatal screening for fragile-X?

Authors:  G E Palomaki; J E Haddow
Journal:  Lancet       Date:  1993-02-06       Impact factor: 79.321

6.  Clinical screening score for the fragile X (Martin-Bell) syndrome.

Authors:  S Laing; M Partington; H Robinson; G Turner
Journal:  Am J Med Genet       Date:  1991 Feb-Mar

7.  Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox.

Authors:  Y H Fu; D P Kuhl; A Pizzuti; M Pieretti; J S Sutcliffe; S Richards; A J Verkerk; J J Holden; R G Fenwick; S T Warren
Journal:  Cell       Date:  1991-12-20       Impact factor: 41.582

8.  Population screening for fragile X.

Authors:  G Turner; H Robinson; S Laing; M van den Berk; A Colley; A Goddard; S Sherman; M Partington
Journal:  Lancet       Date:  1992-05-16       Impact factor: 79.321

9.  Absence of expression of the FMR-1 gene in fragile X syndrome.

Authors:  M Pieretti; F P Zhang; Y H Fu; S T Warren; B A Oostra; C T Caskey; D L Nelson
Journal:  Cell       Date:  1991-08-23       Impact factor: 41.582

10.  Population incidence and segregation ratios in the Martin-Bell syndrome.

Authors:  T P Webb; S E Bundey; A I Thake; J Todd
Journal:  Am J Med Genet       Date:  1986 Jan-Feb
View more
  43 in total

Review 1.  Investigation of children with "developmental delay".

Authors:  Louise Hartley; Alison Salt; Jon Dorling; Paul Gringras
Journal:  West J Med       Date:  2002-01

Review 2.  Telomeres: a diagnosis at the end of the chromosomes.

Authors:  B B A De Vries; R Winter; A Schinzel; C van Ravenswaaij-Arts
Journal:  J Med Genet       Date:  2003-06       Impact factor: 6.318

3.  Comparative frequency of fragile-X (FMR1) and creatine transporter (SLC6A8) mutations in X-linked mental retardation.

Authors:  J L Mandel
Journal:  Am J Hum Genet       Date:  2004-10       Impact factor: 11.025

Review 4.  X linked mental retardation: a clinical guide.

Authors:  F L Raymond
Journal:  J Med Genet       Date:  2005-08-23       Impact factor: 6.318

Review 5.  Role of hippocampal NMDA receptors in a mouse model for fragile X mental retardation syndrome.

Authors:  Thomas Mittmann
Journal:  J Physiol       Date:  2009-02-15       Impact factor: 5.182

6.  High-risk fragile x screening in Guatemala: use of a new blood spot polymerase chain reaction technique.

Authors:  Jennifer Yuhas; Paulina Walichiewicz; Ruiqin Pan; Wenting Zhang; E Melina Casillas; Randi J Hagerman; Flora Tassone
Journal:  Genet Test Mol Biomarkers       Date:  2009-12

7.  Clinical studies on submicroscopic subtelomeric rearrangements: a checklist.

Authors:  B B de Vries; S M White; S J Knight; R Regan; T Homfray; I D Young; M Super; C McKeown; M Splitt; O W Quarrell; A H Trainer; M F Niermeijer; S Malcolm; J Flint; J A Hurst; R M Winter
Journal:  J Med Genet       Date:  2001-03       Impact factor: 6.318

8.  Prospective screening for subtelomeric rearrangements in children with mental retardation of unknown aetiology: the Amsterdam experience.

Authors:  C D M van Karnebeek; C Koevoets; S Sluijter; E K Bijlsma; D F M C Smeets; E J Redeker; R C M Hennekam; J M N Hoovers
Journal:  J Med Genet       Date:  2002-08       Impact factor: 6.318

9.  Prevalence and phenotype consequence of FRAXA and FRAXE alleles in a large, ethnically diverse, special education-needs population.

Authors:  D C Crawford; K L Meadows; J L Newman; L F Taft; D L Pettay; L B Gold; S J Hersey; E F Hinkle; M L Stanfield; P Holmgreen; M Yeargin-Allsopp; C Boyle; S L Sherman
Journal:  Am J Hum Genet       Date:  1999-02       Impact factor: 11.025

10.  A rapid polymerase chain reaction-based screening method for identification of all expanded alleles of the fragile X (FMR1) gene in newborn and high-risk populations.

Authors:  Flora Tassone; Ruiqin Pan; Khaled Amiri; Annette K Taylor; Paul J Hagerman
Journal:  J Mol Diagn       Date:  2007-12-28       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.